Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 22 March 2002:
Vol. 295. no. 5563, pp. 2264 - 2267
DOI: 10.1126/science.1067568
Prev | Table of Contents | Next

Reports

Brain to Plasma Amyloid-beta Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

Ronald B. DeMattos,123* Kelly R. Bales,5* David J. Cummins,5 Steven M. Paul,56dagger David M. Holtzman1234dagger

The deposition of amyloid-beta (Abeta ) peptides into amyloid plaques precedes the cognitive dysfunction of Alzheimer's disease (AD) by years. Biomarkers indicative of brain amyloid burden could be useful for identifying individuals at high risk for developing AD. As in AD in humans, baseline plasma Abeta levels in a transgenic mouse model of AD did not correlate with brain amyloid burden. However, after peripheral administration of a monoclonal antibody to Abeta (m266), we observed a rapid increase in plasma Abeta and the magnitude of this increase was highly correlated with amyloid burden in the hippocampus and cortex. This method may be useful for quantifying brain amyloid burden in patients at risk for or those who have been diagnosed with AD.

1 Center for the Study of Nervous System Injury,
2 Alzheimer's Disease Research Center,
3 Department of Neurology,
4 Molecular Biology and Pharmacology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.
5 Neuroscience Discovery Research, Eli Lilly and Co., Lilly Research Laboratories, Indianapolis, IN 46285, USA.
6 Departments of Pharmacology, Toxicology, and Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46285, USA.
*   These authors contributed equally to this work.

dagger    To whom correspondence should be addressed. E-mail: holtzman{at}neuro.wustl.edu (D.M.H.) or Paul_Steven_M{at}Lilly.com (S.M.P.)

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
P-Glycoprotein Efflux and Other Factors Limit Brain Amyloid {beta} Reduction by {beta}-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors in Mice.
J. E. Meredith Jr., L. A. Thompson, J. H. Toyn, L. Marcin, D. M. Barten, J. Marcinkeviciene, L. Kopcho, Y. Kim, A. Lin, V. Guss, et al. (2008)
J. Pharmacol. Exp. Ther. 326, 502-513
   Abstract »    Full Text »    PDF »
Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease?.
X. Sun, D. C. Steffens, R. Au, M. Folstein, P. Summergrad, J. Yee, I. Rosenberg, D. M. Mwamburi, and W. Q. Qiu (2008)
Arch Gen Psychiatry 65, 542-550
   Abstract »    Full Text »    PDF »
Experimental Investigation of Antibody-Mediated Clearance Mechanisms of Amyloid- in CNS of Tg-SwDI Transgenic Mice.
V. Vasilevko, F. Xu, M. L. Previti, W. E. Van Nostrand, and D. H. Cribbs (2007)
J. Neurosci. 27, 13376-13383
   Abstract »    Full Text »    PDF »
Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization.
W.-P. Chang, D. Downs, X.-P. Huang, H. Da, K.-M. Fung, and J. Tang (2007)
FASEB J 21, 3184-3196
   Abstract »    Full Text »    PDF »
Anti-Abeta1 11 Antibody Binds to Different beta-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers.
G. Mamikonyan, M. Necula, M. Mkrtichyan, A. Ghochikyan, I. Petrushina, N. Movsesyan, E. Mina, A. Kiyatkin, C. G. Glabe, D. H. Cribbs, et al. (2007)
J. Biol. Chem. 282, 22376-22386
   Abstract »    Full Text »    PDF »
Evidence of a Role for Lactadherin in Alzheimer's Disease.
J. Boddaert, K. Kinugawa, J.-C. Lambert, F. Boukhtouche, J. Zoll, R. Merval, O. Blanc-Brude, D. Mann, C. Berr, J. Vilar, et al. (2007)
Am. J. Pathol. 170, 921-929
   Abstract »    Full Text »    PDF »
Fibrillar and Oligomeric beta-Amyloid as Distinct Local Biomarkers for Alzheimer's Disease.
M. C MONTALTO, G. FARRAR, and C. T. HEHIR (2007)
Ann. N.Y. Acad. Sci. 1097, 239-258
   Abstract »    Full Text »    PDF »
Insights into the mechanisms of action of anti-A{beta} antibodies in Alzheimer's disease mouse models.
Y. Levites, L. A. Smithson, R. W. Price, R. S. Dakin, B. Yuan, M. R. Sierks, J. Kim, E. McGowan, D. K. Reed, T. L. Rosenberry, et al. (2006)
FASEB J 20, 2576-2578
   Abstract »    Full Text »    PDF »
Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid beta, Amyloid beta40, and Amyloid beta42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice..
Y. Levites, K. Jansen, L. A. Smithson, R. Dakin, V. M. Holloway, P. Das, and T. E. Golde (2006)
J. Neurosci. 26, 11923-11928
   Abstract »    Full Text »    PDF »
Therapeutic approaches to Alzheimer's disease.
H.-W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang (2006)
Brain 129, 2840-2855
   Abstract »    Full Text »    PDF »
Papillomavirus-Like Particles Are an Effective Platform for Amyloid-beta Immunization in Rabbits and Transgenic Mice.
E. Zamora, A. Handisurya, S. Shafti-Keramat, D. Borchelt, G. Rudow, K. Conant, C. Cox, J. C. Troncoso, and R. Kirnbauer (2006)
J. Immunol. 177, 2662-2670
   Abstract »    Full Text »    PDF »
Detection of oligomeric forms of {alpha}-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
O. M. A. El-Agnaf, S. A. Salem, K. E. Paleologou, M. D. Curran, M. J. Gibson, J. A. Court, M. G. Schlossmacher, and D. Allsop (2006)
FASEB J 20, 419-425
   Abstract »    Full Text »    PDF »
A{beta} peptide immunization restores blood-brain barrier integrity in Alzheimer disease.
D. L. Dickstein, K. E. Biron, M. Ujiie, C. G. Pfeifer, A. R. Jeffries, and W. A. Jefferies (2006)
FASEB J 20, 426-433
   Abstract »    Full Text »    PDF »
Plasma {beta}-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
M. E. Gurol, M. C. Irizarry, E. E. Smith, S. Raju, R. Diaz-Arrastia, T. Bottiglieri, J. Rosand, J. H. Growdon, and S. M. Greenberg (2006)
Neurology 66, 23-29
   Abstract »    Full Text »    PDF »
A Dynamic Relationship between Intracellular and Extracellular Pools of A{beta}.
S. Oddo, A. Caccamo, I. F. Smith, K. N. Green, and F. M. LaFerla (2006)
Am. J. Pathol. 168, 184-194
   Abstract »    Full Text »    PDF »
The Neuronal and Immune Memory Systems as Supervisors of Neural Plasticity and Aging of the Brain: From Phenomenology to Coding of Information.
K. D. JOVANOVA-NESIC and B. D. JANKOVIC (2005)
Ann. N.Y. Acad. Sci. 1057, 279-295
   Abstract »    Full Text »    PDF »
Association of homocysteine with plasma amyloid {beta} protein in aging and neurodegenerative disease.
M. C. Irizarry, M. E. Gurol, S. Raju, R. Diaz-Arrastia, J. J. Locascio, M. Tennis, B. T. Hyman, J. H. Growdon, S. M. Greenberg, and T. Bottiglieri (2005)
Neurology 65, 1402-1408
   Abstract »    Full Text »    PDF »
Hyperinsulinemia Provokes Synchronous Increases in Central Inflammation and {beta}-Amyloid in Normal Adults.
M. A. Fishel, G. S. Watson, T. J. Montine, Q. Wang, P. S. Green, J. J. Kulstad, D. G. Cook, E. R. Peskind, L. D. Baker, D. Goldgaber, et al. (2005)
Arch Neurol 62, 1539-1544
   Abstract »    Full Text »    PDF »
Dense-Core Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer's Disease Are Centered on Vessel Walls.
S. Kumar-Singh, D. Pirici, E. McGowan, S. Serneels, C. Ceuterick, J. Hardy, K. Duff, D. Dickson, and C. Van Broeckhoven (2005)
Am. J. Pathol. 167, 527-543
   Abstract »    Full Text »    PDF »
Mutation of Active Site Residues of Insulin-degrading Enzyme Alters Allosteric Interactions.
E. S. Song, A. Daily, M. G. Fried, M. A. Juliano, L. Juliano, and L. B. Hersh (2005)
J. Biol. Chem. 280, 17701-17706
   Abstract »    Full Text »    PDF »
Autoantibodies to Redox-modified Oligomeric A{beta} Are Attenuated in the Plasma of Alzheimer's Disease Patients.
R. D. Moir, K. A. Tseitlin, S. Soscia, B. T. Hyman, M. C. Irizarry, and R. E Tanzi (2005)
J. Biol. Chem. 280, 17458-17463
   Abstract »    Full Text »    PDF »
Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid {beta}.
M. M. Racke, L. I. Boone, D. L. Hepburn, M. Parsadainian, M. T. Bryan, D. K. Ness, K. S. Piroozi, W. H. Jordan, D. D. Brown, W. P. Hoffman, et al. (2005)
J. Neurosci. 25, 629-636
   Abstract »    Full Text »    PDF »
Immunization therapy for Alzheimer disease?.
D. A. Bennett and D. M. Holtzman (2005)
Neurology 64, 10-12
   Full Text »    PDF »
Amyloid accomplices and enforcers.
A. T. Alexandrescu (2005)
Protein Sci. 14, 1-12
   Abstract »    Full Text »    PDF »
Microglia as a Potential Bridge between the Amyloid {beta}-Peptide and Tau.
M. KITAZAWA, T. R. YAMASAKI, and F. M. LAFERLA (2004)
Ann. N.Y. Acad. Sci. 1035, 85-103
   Abstract »    Full Text »    PDF »
RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid {beta}-Peptide Clearance Through Transport Across the Blood-Brain Barrier.
R. Deane, Z. Wu, and B. V. Zlokovic (2004)
Stroke 35, 2628-2631
   Abstract »    Full Text »    PDF »
Intravenous immunoglobulins containing antibodies against {beta}-amyloid for the treatment of Alzheimer's disease.
R C Dodel, Y Du, C Depboylu, H Hampel, L Frolich, A Haag, U Hemmeter, S Paulsen, S J Teipel, S Brettschneider, et al. (2004)
J. Neurol. Neurosurg. Psychiatry 75, 1472-1474
   Abstract »    Full Text »    PDF »
Alzheimer's Disease A{beta} Vaccine Reduces Central Nervous System A{beta} Levels in a Non-Human Primate, the Caribbean Vervet.
C. A. Lemere, A. Beierschmitt, M. Iglesias, E. T. Spooner, J. K. Bloom, J. F. Leverone, J. B. Zheng, T. J. Seabrook, D. Louard, D. Li, et al. (2004)
Am. J. Pathol. 165, 283-297
   Abstract »    Full Text »    PDF »
Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid {beta}-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid {beta}-Protein Precursor.
J. Davis, F. Xu, R. Deane, G. Romanov, M. L. Previti, K. Zeigler, B. V. Zlokovic, and W. E. Van Nostrand (2004)
J. Biol. Chem. 279, 20296-20306
   Abstract »    Full Text »    PDF »
Studies of A{beta} Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
T. A. Lanz, J. D. Hosley, W. J. Adams, and K. M. Merchant (2004)
J. Pharmacol. Exp. Ther. 309, 49-55
   Abstract »    Full Text »
Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting A{beta} Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial.
C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.-X. Li, A. Tammer, et al. (2003)
Arch Neurol 60, 1685-1691
   Abstract »    Full Text »    PDF »
In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-{beta} Metabolism and Half-Life.
J. R. Cirrito, P. C. May, M. A. O'Dell, J. W. Taylor, M. Parsadanian, J. W. Cramer, J. E. Audia, J. S. Nissen, K. R. Bales, S. M. Paul, et al. (2003)
J. Neurosci. 23, 8844-8853
   Abstract »    Full Text »    PDF »
Human anti-{beta}-amyloid antibodies block {beta}-amyloid fibril formation and prevent {beta}-amyloid-induced neurotoxicity.
Y. Du, X. Wei, R. Dodel, N. Sommer, H. Hampel, F. Gao, Z. Ma, L. Zhao, W. H. Oertel, and M. Farlow (2003)
Brain 126, 1935-1939
   Abstract »    Full Text »    PDF »
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid {beta}-Protein Levels.
H. Fukumoto, M. Tennis, J. J. Locascio, B. T. Hyman, J. H. Growdon, and M. C. Irizarry (2003)
Arch Neurol 60, 958-964
   Abstract »    Full Text »    PDF »
The {gamma}-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl Ester Reduces A{beta} Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice.
T. A. Lanz, C. S. Himes, G. Pallante, L. Adams, S. Yamazaki, B. Amore, and K. M. Merchant (2003)
J. Pharmacol. Exp. Ther. 305, 864-871
   Abstract »    Full Text »    PDF »
Drugs Targeting Alzheimer's Disease: Some Things Old and Some Things New.
M. L. Michaelis (2003)
J. Pharmacol. Exp. Ther. 304, 897-904
   Abstract »    Full Text »    PDF »
Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to beta -Amyloid.
Y. Matsuoka, M. Saito, J. LaFrancois, M. Saito, K. Gaynor, V. Olm, L. Wang, E. Casey, Y. Lu, C. Shiratori, et al. (2003)
J. Neurosci. 23, 29-33
   Abstract »    Full Text »    PDF »
Biological Markers in Alzheimer Disease.
J. Neugroschl and K. L. Davis (2002)
Am J Geriatr Psychiatry 10, 660-677
   Abstract »    Full Text »    PDF »
Evidence That Synaptically Released beta -Amyloid Accumulates as Extracellular Deposits in the Hippocampus of Transgenic Mice.
O. Lazarov, M. Lee, D. A. Peterson, and S. S. Sisodia (2002)
J. Neurosci. 22, 9785-9793
   Abstract »    Full Text »    PDF »
Lipid Metabolism, Epidemiology, and the Mechanisms of Alzheimer's Disease.
R. P. FRIEDLAND (2002)
Ann. N.Y. Acad. Sci. 977, 387-390
   Abstract »    Full Text »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)